Accelerator Documentation – peer reviewed articles

…587, 2008, pages 221-226 M. Eriksson, L.-J. Lindgren, M. Sjöström, E. Wallén, L. Rivkin, A. Streun http://dx.doi.org/10.1016/j.nima.2008.01.068 Prototype soft end dipole magnet for MAX-IV, fabrication and measurements Nucl. Instr. and…

Videos

MAX IV’s videos and documentary material can mainly be found on our YouTube channel. Do you have a video idea? Reach out to communication@maxiv.lu.se. https://www.youtube.com/watch?v=78gfeq-yd8g https://www.youtube.com/watch?v=NJkVYMjmoIs https://www.youtube.com/watch?v=_WNVWZfLGcM https://www.youtube.com/watch?v=K6YyBSmyt74 https://www.youtube.com/watch?v=OyMf5ayqtbI Watch…

CoSAXS Sample Environment

…for magnetic experiments Magnet: GMW 3480 Model.  Max Magnetic field at the sample: 2 Tesla for 20 mm diameter poles.  Max continuous power operation (water cooled) 35 A, 60 V …

Staff and organisation

…classical step scans to continuous mesh scans and tomography scans. For our MX beamlines we develop and support the MXCube experiment platform. We also provide many types of user interfaces,…

X-ray eyes on artifact from shipwreck Gribshunden

…different from one another, and it’s the same with all of the mail armour links recovered from Gribshunden. The maker’s mark alloy composition is unique, too. It’s far more complex…

Prepare sample shipments with EXI at MAX IV

…the shipping labels and who will receive notifications about the dewar. On the top menu bar, select Manage shipping address from the Shipment drop down menu. Select List to show…

Practical information

…Uardavägen 131 Monday – Sunday 8am-9pm 1,7 km Tram, 3 stops to: “Lund Telefonplan” LIDL Magistratsvägen 6 Monday – Friday 8am-9pm Saturday 8am-7pm Sunday 9am-7pm 2,4 km ICA Supermarket Fäladstorget…

Combination of techniques for effective pharmaceutical formulation 

…Berzins. Publication Aljabbari A., Kihara S., Rades T., Boyd BJ., Berzins K. The Influence of Gastrointestinal Biomolecules on Solid-State Transformations in Pharmaceutical Particulates Mol Pharm. 7, 4297 (2023) 10.1021/acs.molpharmaceut.3c00442 open_in_new…